Meeting Coverage:

American Academy of Ophthalmology

AAO: 2019

Clinical Use of Cenegermin-bkbj Ophthalmic Solution for NK

Show Description +

Find out why Giacomina Massaro-Giordano, MD, considers cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) to be a game changer for the treatment of patients with neurotrophic keratitis (NK).

Posted: 9/11/2019

Up Next


Iridocorneal Endothelial Syndrome

Lauren S. Blieden, MD

Advanced Diagnostics in Refractive Surgery: Epithelial Mapping and Phakic IOL Sizing

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Efficacy of Presbyond for the Correction of Presbyopia

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Autonomous AI in Ophthalmology

Michael D. Abramoff, MD, PhD

CXL for Infectious Keratitis

Farhad Hafezi, MD, PhD, FARVO

MIGS and Medications

Alex Huang, MD

Controlling Wound Healing Following PRK

Farhad Hafezi, MD, PhD, FARVO

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS

PANORAMA Study Data

Rishi P. Singh, MD

Gene Therapy for Wet AMD

Szilard Kiss, MD

ABC to Block VEGF-A Isoforms

Charles C. Wykoff, MD, PhD

Surgery for Viral Retinitis

J. Fernando Arevalo, MD, PhD, FACS

Clinical Use of Cenegermin-bkbj Ophthalmic Solution for NK

Find out why Giacomina Massaro-Giordano, MD, considers cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) to be a game changer for the treatment of patients with neurotrophic keratitis (NK).

Posted: 9/11/2019


Please log in to leave a comment.

More From AAO: 2019 Coverage

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS